Click here to search courses using NAPNAP's previous Course Catalog layout.

Title
Category
Credits
Event date
Cost
Navigating Pediatric Obesity Treatment: Exploring the Latest AAP Guidelines and Strategies
  • Primary Care
  • FREE for Members
  • Pharmacology CE
  • 1.00 Contact hours
$0.00
1.0 NAPNAP contact hour of which 0.25 contain pharmacology content. This continuing education activity is offered FREE to Members and Nonmembers. The purpose of this program is to inform primary care pediatric health care providers about the management of children and adolescents with obesity guided by the American Academy of Pediatrics (AAP) Clinical Practice Guidelines published in 2023. The presentation content focuses on how to implement best practices for the management of children and adolescents with obesity including pharmacotherapy. Additionally, guidance on the AAP resources and how to access and utilize these tools will be discussed.
JPHC CE: Gene Therapy: A New Hope in Sickle Cell Disease Treatment
  • Primary Care
  • FREE for Members
  • Pharmacology CE
  • 1.00 Contact hours
$10.00
1.0 NAPNAP contact hour of which 1.0 contain pharmacology content. This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Sickle cell disease (SCD) is a lifelong disease requiring expensive treatment for management and limited curative options until the last few years. Gene therapy has emerged as a curative option for SCD, with two approved therapies available to SCD patients aged greater than 12 years. Consideration must be considered regarding the ethics, efficacy, management requirements, education, and counseling needs of patients and their parents. Current and future practices will need to advocate for improved access and affordability of this specialized care and address the unknown and less defined areas of gene therapy pertaining to SCD through research. J Pediatr Health Care. (2025) 39, Issue 1, 122-128.
JPHC CE: Approaches to Treating Children With ADHD and Common Comorbidities
  • FREE for Members
  • Pharmacology CE
  • Psychopharmacology CE
  • Controlled Substances CE
  • 1.00 Contact hours
$10.00
1.0 NAPNAP contact hour of which 1.0 contain pharmacology content (Rx), (1.0 is related to psychopharmacology), (0.25 is related to controlled substance). This continuing education activity is offered free to NAPNAP Members. For nonmembers, this continuing education activity rate is $10. Attention Deficit Hyperactivity Disorder (ADHD) is the most common mental health disorder among children and adolescents, with a prevalence rate of 9.8% in children 3 to 17 years of age (Bitsko et al., 2022). The American Academy of Pediatrics (AAP) has published guidelines for treatment of ADHD in children and adolescents ages 4 to 17 years that address diagnosis, treatment and monitoring of ADHD (Wolraich et al., 2019). The AAP guidelines do not address treatment of children with co-morbidities but identify the treatment of ADHD in children with comorbidities as an area for future research. To address this gap, a review of ADHD treatment in children with comorbidities including anxiety, depression, substance use disorder (SUD), epilepsy, tic disorders (TD), oppositional defiant disorder (ODD), learning disabilities (LD), autism spectrum disorder (ASD) and sleep disorders was conducted. J Pediatr Health Care. (2025) 39, 318-325.